Cargando…

High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study

ABSTRACT: Wilms’ tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its signi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jae-Ho, Kim, Hee-Je, Kwak, Dae-Hun, Park, Sung-Soo, Jeon, Young-Woo, Lee, Sung-Eun, Cho, Byung-Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong Wook, Min, Woo-Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259829/
https://www.ncbi.nlm.nih.gov/pubmed/28114959
http://dx.doi.org/10.1186/s13045-017-0404-4
_version_ 1782499282239094784
author Yoon, Jae-Ho
Kim, Hee-Je
Kwak, Dae-Hun
Park, Sung-Soo
Jeon, Young-Woo
Lee, Sung-Eun
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Lee, Seok
Min, Chang-Ki
Cho, Seok-Goo
Kim, Dong-Wook
Lee, Jong Wook
Min, Woo-Sung
author_facet Yoon, Jae-Ho
Kim, Hee-Je
Kwak, Dae-Hun
Park, Sung-Soo
Jeon, Young-Woo
Lee, Sung-Eun
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Lee, Seok
Min, Chang-Ki
Cho, Seok-Goo
Kim, Dong-Wook
Lee, Jong Wook
Min, Woo-Sung
author_sort Yoon, Jae-Ho
collection PubMed
description ABSTRACT: Wilms’ tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its significance for relapse prediction. In this single center retrospective study, we serially measured PML-RARa and WT1 expression from 117 APL patients at diagnosis, at post-induction and post-consolidation chemotherapies, and at every 3 months after starting maintenance therapy. All 117 patients were in molecular remission after treatment of at least 2 consolidation chemotherapies. We used WT1 ProfileQuant™ kit (Ipsogen) for WT1 monitoring. High WT1 expression (>120 copies/10(4) ABL1) after consolidation and at early period (3 months) after maintenance therapy significantly predicted subsequent relapse. All paired PML-RARa RQ-PCR were not detected except for one sample with early relapse. Patients with high WT1 expression at 3 months after maintenance therapy (n = 40) showed a significantly higher relapse rate (30.5 vs. 6.9%, P < 0.001) and inferior disease free survival (62.8 vs. 91.4%, P < 0.001). Multivariate analysis revealed that high peak leukocyte counts at diagnosis (HR = 6.4, P < 0.001) and high WT1 expression at 3 months after maintenance therapy (HR = 7.1, P < 0.001) were significant factors for prediction of relapse. Our data showed high post-remission WT1 expression was a reliable marker for prediction of subsequent molecular relapse in APL. In this high-risk group, early intervention with ATRA ± ATO, anti-CD33 antibody therapy, and WT1-specific therapy may be used for relapse prevention. TRIAL REGISTRATION: Clinical Research Information Service (CRIS), KCT0002079 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0404-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5259829
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52598292017-01-26 High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study Yoon, Jae-Ho Kim, Hee-Je Kwak, Dae-Hun Park, Sung-Soo Jeon, Young-Woo Lee, Sung-Eun Cho, Byung-Sik Eom, Ki-Seong Kim, Yoo-Jin Lee, Seok Min, Chang-Ki Cho, Seok-Goo Kim, Dong-Wook Lee, Jong Wook Min, Woo-Sung J Hematol Oncol Letter to the Editor ABSTRACT: Wilms’ tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its significance for relapse prediction. In this single center retrospective study, we serially measured PML-RARa and WT1 expression from 117 APL patients at diagnosis, at post-induction and post-consolidation chemotherapies, and at every 3 months after starting maintenance therapy. All 117 patients were in molecular remission after treatment of at least 2 consolidation chemotherapies. We used WT1 ProfileQuant™ kit (Ipsogen) for WT1 monitoring. High WT1 expression (>120 copies/10(4) ABL1) after consolidation and at early period (3 months) after maintenance therapy significantly predicted subsequent relapse. All paired PML-RARa RQ-PCR were not detected except for one sample with early relapse. Patients with high WT1 expression at 3 months after maintenance therapy (n = 40) showed a significantly higher relapse rate (30.5 vs. 6.9%, P < 0.001) and inferior disease free survival (62.8 vs. 91.4%, P < 0.001). Multivariate analysis revealed that high peak leukocyte counts at diagnosis (HR = 6.4, P < 0.001) and high WT1 expression at 3 months after maintenance therapy (HR = 7.1, P < 0.001) were significant factors for prediction of relapse. Our data showed high post-remission WT1 expression was a reliable marker for prediction of subsequent molecular relapse in APL. In this high-risk group, early intervention with ATRA ± ATO, anti-CD33 antibody therapy, and WT1-specific therapy may be used for relapse prevention. TRIAL REGISTRATION: Clinical Research Information Service (CRIS), KCT0002079 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0404-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-23 /pmc/articles/PMC5259829/ /pubmed/28114959 http://dx.doi.org/10.1186/s13045-017-0404-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Yoon, Jae-Ho
Kim, Hee-Je
Kwak, Dae-Hun
Park, Sung-Soo
Jeon, Young-Woo
Lee, Sung-Eun
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Lee, Seok
Min, Chang-Ki
Cho, Seok-Goo
Kim, Dong-Wook
Lee, Jong Wook
Min, Woo-Sung
High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
title High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
title_full High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
title_fullStr High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
title_full_unstemmed High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
title_short High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
title_sort high wt1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative pml-rara after anthracycline-based chemotherapy: a single-center cohort study
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259829/
https://www.ncbi.nlm.nih.gov/pubmed/28114959
http://dx.doi.org/10.1186/s13045-017-0404-4
work_keys_str_mv AT yoonjaeho highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT kimheeje highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT kwakdaehun highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT parksungsoo highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT jeonyoungwoo highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT leesungeun highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT chobyungsik highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT eomkiseong highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT kimyoojin highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT leeseok highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT minchangki highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT choseokgoo highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT kimdongwook highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT leejongwook highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy
AT minwoosung highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy